{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T12:12:32Z","timestamp":1778587952113,"version":"3.51.4"},"reference-count":78,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"publisher","award":["R34DA052178"],"award-info":[{"award-number":["R34DA052178"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["AIDS Behav"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1007\/s10461-025-04978-3","type":"journal-article","created":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T07:24:16Z","timestamp":1764573856000},"page":"1338-1351","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Feasibility, Acceptability, and Preliminary Efficacy of a Pilot Study To Integrate Buprenorphine into a Harm-reduction Drop-in-Center in Kampala, Uganda"],"prefix":"10.1007","volume":"30","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9388-847X","authenticated-orcid":false,"given":"Julia","family":"Dickson-Gomez","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sergey","family":"Tarima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wamala","family":"Twaibu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dan","family":"Katende","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Latifah","family":"Kyeswa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura","family":"Glasman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arthur","family":"Kiconco","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sarah","family":"Krechel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bryan","family":"Johnston","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Moses","family":"Ogwal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brian Byamah","family":"Mutamba","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Mudiope","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stella","family":"Alamo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rhoda","family":"Wanyenze","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Geofrey","family":"Musinguzi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,12,1]]},"reference":[{"issue":"11","key":"4978_CR1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/09540121.2013.766303","volume":"25","author":"AW Batchelder","year":"2013","unstructured":"Batchelder AW, et al. \u201cDamaging what wasn\u2019t damaged already\u201d: Psychological tension and antiretroviral adherence among HIV-infected methadone-maintained drug users. AIDS Care. 2013;25(11):1\u20135.","journal-title":"AIDS Care"},{"key":"4978_CR2","doi-asserted-by":"publisher","DOI":"10.1016\/j.josat.2025.209742","volume":"176","author":"M Bolshakova","year":"2025","unstructured":"Bolshakova M, et al. Perspectives on medication for opioid use disorder (MOUD) access and service delivery among a community sample of people who use opioids in Los Angeles. J Subst Use Addict Treat. 2025;176:209742.","journal-title":"J Subst Use Addict Treat"},{"key":"4978_CR3","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugpo.2024.104559","volume":"132","author":"H Byles","year":"2024","unstructured":"Byles H, et al. Barriers to calling emergency services amongst people who use substances in the event of overdose: a scoping review. Int J Drug Policy. 2024;132:104559.","journal-title":"Int J Drug Policy"},{"key":"4978_CR4","doi-asserted-by":"publisher","first-page":"1588","DOI":"10.1111\/j.1360-0443.2011.03482.x","volume":"106","author":"JS Cacciola","year":"2011","unstructured":"Cacciola JS, et al. Recent status scores for version 6 of the Addiction Severity Index (ASI-6). Addiction. 2011;106:1588\u2013602.","journal-title":"Addiction"},{"issue":"7","key":"4978_CR5","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1176\/appi.ajp.2008.07111835","volume":"165","author":"KM Carroll","year":"2008","unstructured":"Carroll KM, et al. Computer-assisted delivery of cognitive-behavioral therapy for addiction: a randomized trial of CBT4CBT. Am J Psychiatry. 2008;165(7):881\u20138.","journal-title":"Am J Psychiatry"},{"key":"4978_CR6","doi-asserted-by":"crossref","unstructured":"67. Colledge-Frisby, S., et al., Global coverage of interventions to prevent and manage drug-related harms among people who inject drugs: a systematic review. Lancet, 2023. 11: p. e673-83.","DOI":"10.1016\/S2214-109X(23)00058-X"},{"key":"4978_CR7","doi-asserted-by":"crossref","unstructured":"25. Cooke, A., et al., Convenience without disclosure: a formative research study of a proposed integrated methadone and antiretroviral therapy service delivery model in Dar es Salaam, Tanzania. Addiction Science and Clinical Practice, 2017. 12(23).","DOI":"10.1186\/s13722-017-0089-6"},{"issue":"9904","key":"4978_CR8","doi-asserted-by":"publisher","first-page":"1564","DOI":"10.1016\/S0140-6736(13)61530-5","volume":"382","author":"L Degenhardt","year":"2013","unstructured":"Degenhardt L, et al. Global burden of disease attributable to illicit drug use and dependence: findings from the Global Burden of Disease Study 2010. Lancet. 2013;382(9904):1564\u201374.","journal-title":"Lancet"},{"key":"4978_CR9","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.drugpo.2013.08.004","volume":"25","author":"L Degenhardt","year":"2014","unstructured":"Degenhardt L, et al. What has been achieved in HIV prevention, treatment and care for people who inject drugs 2010\u20132012? A review of the six highest burden countries. Int J Drug Policy. 2014;25:53\u201360.","journal-title":"Int J Drug Policy"},{"key":"4978_CR10","doi-asserted-by":"crossref","unstructured":"10. Degenhardt, L., et al., Global prevalence of injecting drug use and sociodemographic characteristics and prevalence of HIV, HBV, and HCV in people who inject drugs: a multistage systematic review. Lancet Global Health, 2017. 5: p. e1192-207.","DOI":"10.1016\/S2214-109X(17)30375-3"},{"key":"4978_CR11","doi-asserted-by":"crossref","unstructured":"21. Degenhardt, L., et al., Prevention of HIV infection for people who inject drugs: why individual, structural, and combination approaches are needed. Lancet, 2010. 376: p. 285\u2013301.","DOI":"10.1016\/S0140-6736(10)60742-8"},{"key":"4978_CR12","doi-asserted-by":"crossref","unstructured":"43. Fox, A.D., et al., Development and evaluation of a community-based buprenorphine treatment intervention. Harm Reduction Journal, 2017. 14(23).","DOI":"10.1186\/s12954-017-0149-y"},{"key":"4978_CR13","doi-asserted-by":"publisher","DOI":"10.3390\/ijerph191610382","author":"J Dickson-Gomez","year":"2022","unstructured":"Dickson-Gomez J, et al. The role of context in integrating buprenorphine into a drop-in center in Kampala, Uganda, using the Consolidated Framework for Implementation Research. Int J Environ Res Public Health. 2022. https:\/\/doi.org\/10.3390\/ijerph191610382.","journal-title":"Int J Environ Res Public Health"},{"key":"4978_CR14","volume":"16","author":"J Dickson-Gomez","year":"2022","unstructured":"Dickson-Gomez J, et al. You\u2019re not supposed to be on it forever\": medications to treat opioid use disorder (MOUD) related stigma among drug treatment providers and people who use opioids. Subst Abuse. 2022;16:11782218221103859.","journal-title":"Subst Abuse"},{"issue":"2","key":"4978_CR15","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1089\/apc.2013.0179","volume":"28","author":"ML Drainoni","year":"2014","unstructured":"Drainoni ML, et al. Patient perspectives of an integrated program of medical care and substance use treatment. AIDS Patient Care STDs. 2014;28(2):71\u201381.","journal-title":"AIDS Patient Care STDs"},{"key":"4978_CR16","doi-asserted-by":"crossref","unstructured":"40. Egan, J.E., et al., Patient perspectives on buprenorphine\/naloxone treatment in the context of HIV care. J Acquir Immune Defic Syndr., 2011. 56: p. S46-53.","DOI":"10.1097\/QAI.0b013e3182097561"},{"key":"4978_CR17","unstructured":"29. ICAP at Columbia University, First methadone clinic opens in Tanzania\u2019s Lake Victoria region. 2018."},{"issue":"3","key":"4978_CR18","doi-asserted-by":"publisher","first-page":"e203","DOI":"10.1097\/ADM.0000000000000912","volume":"16","author":"VS Ganetsky","year":"2022","unstructured":"Ganetsky VS, et al. A low-threshold comprehensive shared medical appointment program for perinatal substance use in an underserved population. J Addict Med. 2022;16(3):e203\u20139.","journal-title":"J Addict Med"},{"key":"4978_CR19","doi-asserted-by":"crossref","unstructured":"74. Grande, L.A., et al., Evidence on buprenorphine dose limits: A review. Journal of Addiction Medicine, 2023. 17(5): p. 509\u2013516.","DOI":"10.1097\/ADM.0000000000001189"},{"issue":"9","key":"4978_CR20","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1080\/09540121.2017.1300634","volume":"29","author":"A Guise","year":"2017","unstructured":"Guise A, et al. Integrated opioid substitution therapy and HIV care: a qualitative systematic review and synthesis of client and provider experiences. AIDS Care. 2017;29(9):1119\u201328.","journal-title":"AIDS Care"},{"key":"4978_CR21","doi-asserted-by":"publisher","DOI":"10.3390\/ijerph16050728","author":"S Hassan","year":"2019","unstructured":"Hassan S, et al. Evaluating the integrated methadone and anti-retroviral therapy strategy in Tanzania using the RE-AIM framework. Int J Environ Res Public Health. 2019. https:\/\/doi.org\/10.3390\/ijerph16050728.","journal-title":"Int J Environ Res Public Health"},{"key":"4978_CR22","unstructured":"15. NACC, HIV prevention response and modes of transmission analysis, final report. 2009, National AIDS Control Council: Nairobi."},{"key":"4978_CR23","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/j.drugpo.2015.10.006","volume":"30","author":"AL Hobkirk","year":"2016","unstructured":"Hobkirk AL, et al. A qualitative study of methamphetamine initiation in Cape Town, South Africa. Int J Drug Policy. 2016;30:99\u2013106.","journal-title":"Int J Drug Policy"},{"key":"4978_CR24","unstructured":"30. ICAP at Columbia University, Mentoring Kenyan Public Health practioners on caring for people who inject drugs. 2016."},{"key":"4978_CR25","unstructured":"52. Joe, G.W., et al., Needle use and sex risk indices: a methodological report, in Research in Progress. 1990, NIDA: Washington, D.C. p. 7\u201310."},{"key":"4978_CR26","doi-asserted-by":"publisher","DOI":"10.1186\/s13722-024-00444-y","author":"B Kamusiime","year":"2024","unstructured":"Kamusiime B, et al. \u201cTake services to the people\u201d: strategies to optimize uptake of PrEP and harm reduction services among people who inject drugs in Uganda. Addict Sci Clin Pract. 2024. https:\/\/doi.org\/10.1186\/s13722-024-00444-y.","journal-title":"Addict Sci Clin Pract"},{"key":"4978_CR27","doi-asserted-by":"publisher","DOI":"10.1186\/s13722-022-00352-z","author":"SK Kiburi","year":"2022","unstructured":"Kiburi SK, Mwangi J, Maina G. Exploring the experiences of clients receiving opioid use disorder treatment at a methadone clinic in Kenya: a qualitative study. Addict Sci Clin Pract. 2022. https:\/\/doi.org\/10.1186\/s13722-022-00352-z.","journal-title":"Addict Sci Clin Pract"},{"key":"4978_CR28","doi-asserted-by":"publisher","DOI":"10.1186\/s13722-023-00374-1","author":"D Knight","year":"2023","unstructured":"Knight D, et al. Economic, social, and clinic influences on opioid treatment program retention in Dar es Salaam, Tanzania: a qualitative study. Addict Sci Clin Pract. 2023. https:\/\/doi.org\/10.1186\/s13722-023-00374-1.","journal-title":"Addict Sci Clin Pract"},{"key":"4978_CR29","doi-asserted-by":"crossref","unstructured":"73. Krawczyk, N., et al., Who stays in medication treatment for opioid use disorder? A national study of outpatient specialty treatment settings. Journal of Substance Abuse Treatment, 2022. 126: p. 108329.","DOI":"10.1016\/j.jsat.2021.108329"},{"key":"4978_CR30","doi-asserted-by":"crossref","unstructured":"6. Lancet Global Mental Health Group, et al., Scale up services for mental disorders: a call for action. Lancet, 2007. 370(9594): p. 1241\u20131252.","DOI":"10.1016\/S0140-6736(07)61242-2"},{"key":"4978_CR31","doi-asserted-by":"publisher","DOI":"10.1016\/S0740-5472(99)00025-2","volume":"18","author":"C Leonhard","year":"2000","unstructured":"Leonhard C, et al. The Addiction Severity Index: a field study of internal consistency and validity. J Subst Abuse Treat. 2000;18:129\u2013315.","journal-title":"J Subst Abuse Treat"},{"issue":"6","key":"4978_CR32","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1080\/10826084.2016.1264964","volume":"52","author":"RR Lion","year":"2017","unstructured":"Lion RR, et al. Gender and sex trading among active methamphetamine users in Cape Town, South Africa. Subst Use Misuse. 2017;52(6):773\u201384.","journal-title":"Subst Use Misuse"},{"key":"4978_CR33","doi-asserted-by":"crossref","unstructured":"78. Lofwall, M.R. and S.L. Walsh, A review of buprenorphine diversion and misuse: The current evidence base and experiences from around the world. Journal of Addiction Medicine, 2014. 8(5): p. 315\u2013326.","DOI":"10.1097\/ADM.0000000000000045"},{"key":"4978_CR34","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1016\/j.socscimed.2019.05.027","volume":"232","author":"EF Madden","year":"2019","unstructured":"Madden EF. Intervention stigma: how medication-assisted treatment marginalizes patients and providers. Soc Sci Med. 2019;232:324\u201331.","journal-title":"Soc Sci Med"},{"key":"4978_CR35","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/0740-5472(92)90062-S","volume":"9","author":"AT McLellan","year":"1992","unstructured":"McLellan AT, et al. The fifth edition of the Addiction Severity Index. J Subst Abuse Treat. 1992;9:199\u2013213.","journal-title":"J Subst Abuse Treat"},{"key":"4978_CR36","doi-asserted-by":"crossref","unstructured":"51. McLellan, A.T., et al., The addiction severity index at 25: Contributions and transitions. The AMerican Journal on Addictions, 2006. 15: p. 113\u2013124.","DOI":"10.1080\/10550490500528316"},{"key":"4978_CR37","doi-asserted-by":"crossref","unstructured":"59. Pilarinos, A., et al., Methadone Maintenance Treatment Discontinuation Among Young People use who Opioids in Vancouver, Canada. Can J Psychiatry, 2022: p. 7067437221136468.","DOI":"10.1177\/07067437221136468"},{"key":"4978_CR38","doi-asserted-by":"crossref","unstructured":"37. Mimiaga, M.J., et al., \u201cWe fear the police, and the police fear us\u201d: structural and individual barriers and facilitators to HIV medication maintenance: a qualitative and quantitative needs assessment. AIDS Care, 2010. 22: p. 1305\u20131313.","DOI":"10.1080\/09540121003758515"},{"key":"4978_CR39","doi-asserted-by":"crossref","unstructured":"77. Mitchell, S.G., et al., Uses of diverted methadone and buprenorphine by opioid-addicted individuals in Baltimore, Maryland. American Journal of Addictions, 2009. 18(5): p. 346\u2013355.","DOI":"10.1080\/10550490903077820"},{"key":"4978_CR40","doi-asserted-by":"publisher","DOI":"10.1186\/s12954-024-00965-4","author":"LB Mlunde","year":"2024","unstructured":"Mlunde LB, et al. Adapting a health facility HIV stigma-reduction participatory training intervention to address drug use stigma in HIV care and treatment clinics in Dar es Salaam, Tanzania. Harm Reduct J. 2024. https:\/\/doi.org\/10.1186\/s12954-024-00965-4.","journal-title":"Harm Reduct J"},{"key":"4978_CR41","doi-asserted-by":"crossref","unstructured":"75. Montoya, I.D., et al., Randomized trial of buprenorphine for treatment of concurrent opiate and cocaine dependence. Clinical Pharmocology and Therapeutics, 2004. 75(1): p. 34\u201338.","DOI":"10.1016\/j.clpt.2003.09.004"},{"key":"4978_CR42","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1080\/09540120410001683367","volume":"16","author":"K Morrow","year":"2004","unstructured":"Morrow K, Costello T. HIV, STD and hepatitis prevention among women in methadone maintenance: a qualitative and quantitative needs assessment. AIDS Care. 2004;16:426\u201333.","journal-title":"AIDS Care"},{"key":"4978_CR43","unstructured":"9. Most at Risk Populations Network and Uganda Harm Reduction Network, Drug use related vulnerability to HIV infection among most-at-risk populations in Uganda. 2016."},{"key":"4978_CR44","doi-asserted-by":"publisher","DOI":"10.1186\/s13722-024-00468-4","author":"P Mudiope","year":"2024","unstructured":"Mudiope P, et al. Retention of people who inject drugs enrolled in a \u2018medications for opioid use disorder\u2019 (MOUD) programme in Uganda. Addict Sci Clin Pract. 2024. https:\/\/doi.org\/10.1186\/s13722-024-00468-4.","journal-title":"Addict Sci Clin Pract"},{"key":"4978_CR45","unstructured":"17. NASCOP, Quarterly programme reports, October-December 2016. 2016, National AIDS and STI Control Programme: Nairobi."},{"issue":"9","key":"4978_CR46","doi-asserted-by":"publisher","first-page":"1312","DOI":"10.1080\/10826084.2021.1922450","volume":"56","author":"J Ndimbii","year":"2021","unstructured":"Ndimbii J, et al. Qualitative analysis of community support to methadone access in Kenya. Subst Use Misuse. 2021;56(9):1312\u20139.","journal-title":"Subst Use Misuse"},{"key":"4978_CR47","unstructured":"53. Joe, G.W. and D.D. Simpson, Needle use risks: composite measures and comparisons, in Handbook on AIDS and the Injection Drug User, B. Brown and G.M. Beschner, Editors. 1991, Greenwood Press: Westport, CT."},{"issue":"5","key":"4978_CR48","doi-asserted-by":"publisher","first-page":"e632","DOI":"10.1016\/S2214-109X(23)00111-0","volume":"11","author":"E-U Nelson","year":"2023","unstructured":"Nelson E-U. Harm reduction interventions for people who inject drugs. Lancet Glob Health. 2023;11(5):e632\u20133.","journal-title":"Lancet Glob Health"},{"key":"4978_CR49","doi-asserted-by":"crossref","unstructured":"8. Nyandindi, C., et al., Prevalence of HIV, Hepatitis C and depression among people who inject drugs in Kinondoni Municipality in Dar es Salaam, Tanzania, in Collage on Problems of Drug Dependence. 2013: San Diego, CA.","DOI":"10.1016\/j.drugalcdep.2014.02.461"},{"issue":"3","key":"4978_CR50","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1002\/hup.2228","volume":"27","author":"S Pasche","year":"2012","unstructured":"Pasche S, Myers B. Substance misuse trends in South Africa. Hum Psychopharmacol. 2012;27(3):338\u201341.","journal-title":"Hum Psychopharmacol"},{"key":"4978_CR51","doi-asserted-by":"crossref","unstructured":"39. Korthius, P.T., et al., Reasons for choosing office-based buprenorphine: preference for patient-centered care. Journal of Addiction Medicine, 2010. 4(204\u2013210).","DOI":"10.1097\/ADM.0b013e3181cc9610"},{"key":"4978_CR52","doi-asserted-by":"crossref","unstructured":"22. Reddon, H., B.D.L. Marshall, and M.-J.S. Milloy, Elimination of HIV transmission through novel and established prevention strategies among people who inject drugs. Lancet HIV, 2019. 6: p. E128-36.","DOI":"10.1016\/S2352-3018(18)30292-3"},{"issue":"3","key":"4978_CR53","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2014-007198","volume":"5","author":"T Rhodes","year":"2015","unstructured":"Rhodes T, et al. Is the promise of methadone Kenya\u2019s solution to managing HIV and addiction? A mixed-method mathematical modelling and qualitative study. BMJ Open. 2015;5(3):e007198.","journal-title":"BMJ Open"},{"key":"4978_CR54","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2020.108419","volume":"218","author":"HT Saleem","year":"2021","unstructured":"Saleem HT, et al. Correlates of non-fatal, opioid overdose among women who use opioids in Dar es Salaam, Tanzania. Drug Alcohol Depend. 2021;218:108419.","journal-title":"Drug Alcohol Depend"},{"key":"4978_CR55","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugpo.2021.103287","volume":"96","author":"HT Saleem","year":"2021","unstructured":"Saleem HT, et al. High occurrence of witnessing an opioid overdose in a sample of women who use heroin in Tanzania: implications for overdose prevention. Int J Drug Policy. 2021;96:103287.","journal-title":"Int J Drug Policy"},{"key":"4978_CR56","doi-asserted-by":"crossref","unstructured":"24. Saleem, H., et al., \u201cCan\u2019t you initiate me here?\u201c: Challenges to timely initiation on antiretroviral therapy among methadone clients in Dar es Salaam, Tanzania. International Journal of Drug Policy, 2016. 30: p. 59\u201365.","DOI":"10.1016\/j.drugpo.2015.12.009"},{"key":"4978_CR57","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.693426","author":"S Shukar","year":"2021","unstructured":"Shukar S, et al. Drug shortage: causes, impact, and mitigation strategies. Front Pharmacol. 2021. https:\/\/doi.org\/10.3389\/fphar.2021.693426.","journal-title":"Front Pharmacol"},{"key":"4978_CR58","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jsat.2019.09.003","volume":"107","author":"RL Snow","year":"2019","unstructured":"Snow RL, et al. Patient experiences with a transitional, low-threshold clinic for the treatment of substance use disorder: a qualitative study of a bridge clinic. J Subst Abuse Treat. 2019;107:1\u20137.","journal-title":"J Subst Abuse Treat"},{"issue":"3","key":"4978_CR59","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1080\/10550887.2012.694603","volume":"31","author":"S Stancliff","year":"2012","unstructured":"Stancliff S, et al. Opioid maintenance treatment as a harm reduction tool for opioid-dependent individuals in New York City: the need to expand access to buprenorphine\/naloxone in marginalized populations. J Addict Dis. 2012;31(3):278\u201387.","journal-title":"J Addict Dis"},{"key":"4978_CR60","doi-asserted-by":"crossref","unstructured":"23. Strathdee, S., et al., Towards combination HIV prevention for injecting drug users: addressing adictophobia, apathy and inattention. Current Opinion HIV and AIDS, 2012. 7: p. 320\u2009\u2212\u200925.","DOI":"10.1097\/COH.0b013e32835369ad"},{"key":"4978_CR61","doi-asserted-by":"crossref","unstructured":"34. Strathdee, S., et al., HIV and risk environment for injecting drugusers: the past, present, and future. Lancet, 2010. 376(9737): p. 268\u2013284.","DOI":"10.1016\/S0140-6736(10)60743-X"},{"key":"4978_CR62","doi-asserted-by":"crossref","unstructured":"1. Beckerleg, S., M. Telfer, and G.L. Hundt, The risk of injecting drug use in east Africa: a case study from Kenya. Harm Reduction Journal, 2005. 2(12).","DOI":"10.1186\/1477-7517-2-12"},{"issue":"1","key":"4978_CR63","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1080\/10550887.2016.1100960","volume":"35","author":"C Timko","year":"2016","unstructured":"Timko C, et al. Retention in medication-assisted treatment for opiate dependence: a systematic review. J Addict Dis. 2016;35(1):22\u201335.","journal-title":"J Addict Dis"},{"key":"4978_CR64","doi-asserted-by":"crossref","unstructured":"56. Hutchison, M., et al., Trends and barriers of medication treatment for opioid use disorders: A systematic review and meta-analysis. Journal of Drug Issues, 2023. Online first.","DOI":"10.1177\/00220426231204841"},{"issue":"2","key":"4978_CR65","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1097\/ADM.0000000000000096","volume":"9","author":"R Tringale","year":"2015","unstructured":"Tringale R, et al. The stepped treatment engagement protocol for homeless, needle exchange heroin-dependent patients. J Addict Med. 2015;9(2):163\u20134.","journal-title":"J Addict Med"},{"key":"4978_CR66","doi-asserted-by":"crossref","unstructured":"26. Ubuguyu, O.S., et al., Improvements in health-related quality of life among methadone maintenance clients in Dar es Salaam, Tanzania. International Journal of Drug Policy, 2016. 30: p. 74\u201381.","DOI":"10.1016\/j.drugpo.2016.03.005"},{"key":"4978_CR67","unstructured":"12. Makere University School of Public Health, Crane Survey Report: Bio-behavioral sruveys among groups at increased risk for HIV in Kampala, Uganda, Makerere University of School of Public Health, K. Ministry ofHealth, Uganda,,, and K. Centres for Disease Control and Prevention, Uganda (PEPFAR),,, Editors. 2017, Makerere School of Public Health Kampala, Uganda."},{"key":"4978_CR68","unstructured":"27. Uganda Harm Reduction Network, Needle and Syringe Program Demonstration. 2018, UHRN: Kampala, Uganda."},{"key":"4978_CR69","unstructured":"28. Uganda Harm Reduction Network, Uganda Harm Reduction Network (UHRN) Annual Report, 2017, U.H.R. Network, Editor. 2017, Uganda Harm Reduction Network: Kampala, Uganda."},{"key":"4978_CR70","doi-asserted-by":"crossref","unstructured":"5. Burnhams, N.H., et al., Using respondent-driven sampling (RDS) to recruit illegal poly-substance users in Cape Town, South Africa: implications and future directios. Substance Abuse Treatment, Prevention and Policy, 2016. 11(31).","DOI":"10.1186\/s13011-016-0074-1"},{"key":"4978_CR71","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2019.20622","volume":"3","author":"SE Wakeman","year":"2020","unstructured":"Wakeman SE, et al. Comparative effectiveness of different treatment pathways for opioid use disorder. JAMA Netw Open. 2020;3:e1920622.","journal-title":"JAMA Netw Open"},{"key":"4978_CR72","doi-asserted-by":"publisher","DOI":"10.1186\/s12954-021-00561-w","author":"M Wilson","year":"2022","unstructured":"Wilson M, et al. Personal experience and awareness of opioid overdose occurrence among peers and willingness to administer naloxone in South Africa: findings from a three-city pilot survey of homeless people who use drugs. Harm Reduct J. 2022. https:\/\/doi.org\/10.1186\/s12954-021-00561-w.","journal-title":"Harm Reduct J"},{"key":"4978_CR73","doi-asserted-by":"crossref","unstructured":"61. Winograd, R.P., et al., Implementation and evaluation of Missouri\u2019s Medication First treatment approach for opioid use disorder in publicly-funded substance use treatment programs. Journal of Substance Abuse Treatment, 2019. 108: p. 55\u201364.","DOI":"10.1016\/j.jsat.2019.06.015"},{"key":"4978_CR74","doi-asserted-by":"crossref","unstructured":"76. Xu, K.Y., C.M. Mintz, and N. Presnall, Comparative effectiveness associated with buprenorphine and naltrexone in opioid use disorder an cooccurring polysubstance use. JAMA, 2022. 5: p. e2211363.","DOI":"10.1001\/jamanetworkopen.2022.11363"},{"key":"4978_CR75","doi-asserted-by":"crossref","unstructured":"48. Zanis, D.A., et al., Reliability and validity of he Addiction Severity Index with a homeless sample. Journal of Substance Abuse Treatment, 1994. 11: p. 541\u2013548.","DOI":"10.1016\/0740-5472(94)90005-1"},{"key":"4978_CR76","doi-asserted-by":"crossref","unstructured":"13. Lambdin, B.H., et al., Prevalence and predictors of HCV among a cohort of Opioid treatment patients in Dar es Salaam, Tanzania. International Journal of Drug Policy, 2017. 4564-69.","DOI":"10.1016\/j.drugpo.2017.05.043"},{"key":"4978_CR77","unstructured":"16. NACC and NASCOP, Geographic mapping of Most at Risk Populations for HIV in Kenya. 2012, National AIDS Control Council National AIDS and STI Control Program: Nairobi."},{"key":"4978_CR78","doi-asserted-by":"crossref","unstructured":"20. Baluku, M., T. Wamala, and D. Muhang, HIV- and hepatitis C-related risk behaviors among people who inject drugs in Uganda: implications for policy and programming. Harm Reduction Journal, 2019. 16.","DOI":"10.1186\/s12954-019-0324-4"}],"container-title":["AIDS and Behavior"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10461-025-04978-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10461-025-04978-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10461-025-04978-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T11:36:32Z","timestamp":1778585792000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10461-025-04978-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,1]]},"references-count":78,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["4978"],"URL":"https:\/\/doi.org\/10.1007\/s10461-025-04978-3","relation":{},"ISSN":["1090-7165","1573-3254"],"issn-type":[{"value":"1090-7165","type":"print"},{"value":"1573-3254","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,1]]},"assertion":[{"value":"15 November 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 December 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Research reported in this paper was carried out in compliance with the Helsinki declaration and was approved by Institutional Review Boards at the Medical College of Wisconsin, PRO00038143, Makerere University Research Ethics Committee, Protocol 888 and registered with the Uganda National Council for Science and Technology. All participants provided written informed consent.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval and Consent to Participate"}}]}}